ACE-031 vs IGF-1 LR3
A side-by-side research comparison of ACE-031 and IGF-1 LR3 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ACE-031 | IGF-1 LR3 |
|---|---|---|
| Full name | ACE-031 (Soluble ActRIIB-Fc Fusion) | Insulin-like Growth Factor-1 Long R3 |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Research compound |
| Mechanism | Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes. | Activates IGF-1R while evading IGFBP sequestration. Triggers PI3K/Akt/mTOR for protein synthesis, satellite cell proliferation, and amino acid uptake into muscle. |
| Molecular weight | ~90,000 Da | 9,111 Da |
| Half-life | 10-14 days | 20-30 hours (vs 15 min native) |
| Bioavailability | High (SubQ) | High (SubQ/IM) |
| Typical dose | 0.3-3 mg/kg | 20-50 mcg |
| Frequency | Every 2-4 weeks | Daily (post-workout) |
| Route | Subcutaneous | Subcutaneous or intramuscular injection |
ACE-031 reported benefits
- Multi-ligand pathway inhibition
- Lean mass increase
- Bone density increase
- Infrequent dosing
- Functional strength improvement
IGF-1 LR3 reported benefits
- Potent anabolic effects
- Hyperplasia (new muscle cells)
- Extended half-life
- Enhanced recovery
- Improved nutrient partitioning
- Satellite cell activation
Related comparisons
Research and educational reference only. Not medical advice.